(Q33406742)

English

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

object named as

C Hosing

14

0 references

25

object named as

L Fayad

0 references

Michelle A Fanale

8

object named as

M Fanale

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sattva S Neelapu

6

object named as

S S Neelapu

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Richard E Champlin

23

object named as

R Champlin

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

M Wang

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

N Fowler

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

N Wagner-Bartak

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

L Feng

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Romaguera

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

F Hagemeister

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Y Oki

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

B Pro

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Shah

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S Thomas

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Younes

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

L Zhang

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

K J Newberry

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Desai

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

N Cheng

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Badillo

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Bejarano

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Y Chen

21

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

K H Young

22

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

L Kwak

24

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

2 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1902-1909

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Natural history of follicular grade 3 non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Con

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Stromal gene signatures in large-B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

The incidence, natural history, biology, and treatment of transformed lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

21 January 2018

Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.95

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2013.95

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33406742&oldid=2195330961"